Talis Biomedical Corporation (TLIS) Tops Q2 EPS by 131c

Talis Biomedical Corporation (NASDAQ: TLIS) reported Q2 EPS of ($8.27), $1.31 better than the analyst estimate of ($9.58). Revenue for the quarter came in at $580 thousand versus the consensus estimate of $102.5 thousand.

For earnings history and earnings-related data on Talis Biomedical Corporation (TLIS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c